ARTV vs GILD · $37.3M cap vs P/E 18, rev $7.80B
Artiva Biotherapeutics, Inc. Common Stock (ARTV) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a biotechnology company listed on US.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
Latest reported ARTV revenue for 2025-12-31 was $0. Net income was -$83.9M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. ARTV currently screens at market cap $37.3M.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
ARTV currently screens at market cap $37.3M. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the ARTV and GILD stock pages for the full models.
Not investment advice.